Understanding drug labels and monographs

Identify the document and product

The United States Prescribing Information, often called USPI, is FDA-approved professional labelling for a drug under labelled conditions of use. It is written primarily for health professionals. In Canada, a Product Monograph is the Canadian product information associated with an authorized drug. Health Canada’s Drug Product Database, or DPD, provides product records and links to human drug monographs. These belong to different national regulatory systems and may not match word for word.

Check the active ingredient, brand or generic name, strength, dosage form, and route. Similar names or the same ingredient can appear in multiple products, and a label for one formulation may not apply to another. A Canadian Drug Identification Number, or DIN, can help distinguish a product listing. Confirm the market and document date before reading further.

Using the Canadian DPD

The DPD can be searched by product characteristics or DIN. Health Canada says it includes information about Canadian drug availability and product monographs for human drugs, and is updated nightly. Open the listing for the exact product and check its status and document. A search result should not be treated as interchangeable with another formulation or brand.

Product information can be revised as new safety information becomes available. Note the revision date and confirm the document matches the product in question. Health Canada also provides answers to common questions about monographs, including how to find authorized product information. If a document is difficult to locate, ask a pharmacist or contact an appropriate health professional rather than assuming a document from another market applies.

Read safety sections in context

Common sections include indications and clinical use, contraindications, warnings and precautions, adverse reactions, interactions, and use in specific populations. Contraindications describe circumstances in which a product should not be used according to its approved information. Warnings and precautions identify important risks or considerations. A warning is not a prediction about what will happen to an individual.

An adverse reaction listed in a label does not mean everyone experiences it. The interaction section may not cover every possible combination of medicines, foods, or substances. A pharmacist or prescriber can interpret the information against a person’s full medication list and health history. Avoid making decisions based on a single sentence or search engine snippet without the complete document.

Use information and limits

Dosage and administration sections describe labelled use for a specific product and clinical context. They may contain technical information about routes, preparation, or adjustments, but this guide is not a source of dosing advice. Do not use a label from another country or formulation to change medication use. Ask a pharmacist or prescriber to explain unclear or conflicting directions.

Labels may also cover pharmacology, storage, overdose information, and how a product is supplied. Professional and patient-facing materials can differ in detail. Keep the package information for the exact product and contact a health professional for personal decisions.

Compare US FDA labels and Canadian monographs

The FDA USPI and Canadian Product Monograph are prepared within different regulatory frameworks. Approved uses, warnings, phrasing, and update timing can differ. Different wording does not automatically mean one source is wrong. Differences can reflect national review histories, product versions, or regulatory decisions. For a Canadian product, consult Canadian authorized information. A US document can identify a question to raise, but should not replace the Canadian monograph.

FDA resources describe differences among databases. Drugs@FDA includes the most recent FDA-approved prescribing information, while certain company-submitted labeling databases may display information that does not match the last FDA-approved version. Note what each database contains and the date. For Canadian authorization and product documents, use Health Canada’s DPD.

What to do when information conflicts

Check exact product identity, country, and revision date. Confirm whether the wording appears under contraindications, warnings, adverse reactions, or another section. Read the surrounding material, because a phrase taken out of context can be misleading. Do not assume the oldest or newest-looking search result is appropriate for the product in hand.

Bring the package, document, or exact section to a pharmacist or prescriber. Ask how it applies to the specific product and situation, and whether there is a more current authorized document. Official information helps explain a product, but a health professional can address how it relates to individual circumstances.

Frequently asked questions

Sources

• Health Canada: Drug Product Database(opens in a new tab)
• Health Canada: Product monograph FAQs(opens in a new tab)
• FDA: Prescribing Information Resources(opens in a new tab)
• FDA: Approved drug information(opens in a new tab)

Written by the Chronic Pain Canada editorial team from the sources listed. Last updated October 2026.